Indian drug maker Alembic Pharmaceuticals revealed that it has settled a patent case with Novartis over Rivastigmine Tartrate capsules which are used in treating dementia.
The company said that it had partnered an American company, Breckenridge Pharmaceuticals, in settling the Paragraph IV patent litigation with Novartis.
AdvertisementFollowing this settlement, Alembic Pharmaceuticals said Novartis has given them the license to market the generic version of capsules before the date of the patent expiry.
P Judge Rules That Anorexic Student Must be Force Fed Illicit Drug 'Ecstasy' May Help Curb Parkinson's M
You May Also Like